UA98122C2 - Sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors - Google Patents

Sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors

Info

Publication number
UA98122C2
UA98122C2 UAA200903909A UAA200903909A UA98122C2 UA 98122 C2 UA98122 C2 UA 98122C2 UA A200903909 A UAA200903909 A UA A200903909A UA A200903909 A UAA200903909 A UA A200903909A UA 98122 C2 UA98122 C2 UA 98122C2
Authority
UA
Ukraine
Prior art keywords
disorders
compounds
disorder
antagonists
disease
Prior art date
Application number
UAA200903909A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Баккер Воутер И. Ивема
Гискиас Г. Кейзер
дер Ньот Мартина А.В. ван
Корнелис Г. Крузе
Лувезейн Арнольд Ван
Ян Зоргдрагер
Original Assignee
Сольве Фармасьютикалз Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сольве Фармасьютикалз Б.В. filed Critical Сольве Фармасьютикалз Б.В.
Priority claimed from PCT/EP2007/059944 external-priority patent/WO2008034863A2/en
Publication of UA98122C2 publication Critical patent/UA98122C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

This invention concerns sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-HTreceptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1), wherein the symbols have the meanings given in the description.
UAA200903909A 2006-09-22 2007-09-20 Sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors UA98122C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121087 2006-09-22
PCT/EP2007/059944 WO2008034863A2 (en) 2006-09-22 2007-09-20 Sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists

Publications (1)

Publication Number Publication Date
UA98122C2 true UA98122C2 (en) 2012-04-25

Family

ID=37768757

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200903909A UA98122C2 (en) 2006-09-22 2007-09-20 Sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors

Country Status (1)

Country Link
UA (1) UA98122C2 (en)

Similar Documents

Publication Publication Date Title
MX2009003183A (en) Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists.
PH12013502376A1 (en) Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
DE69705608T2 (en) TROPANDERIVATES, THEIR PRODUCTION AND USE
EP1910321A4 (en) New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease
NO20092688L (en) Compounds with a combination of cannabinoid CB1 antagonism and acetylcholinesterase inhibition
MX2009005509A (en) 2-aminoquinolines as 5-ht(5a) receptor antagonists.
NZ592563A (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
MX2010009643A (en) 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists.
TW200833327A (en) 4-imidazolines as TAAR's ligands
MX2016001080A (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof.
WO2003016274A3 (en) 2-substituted piperidines that are ligands for monoamine receptors and transporters
MX2009007405A (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition.
UA98122C2 (en) Sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors
MX2010008239A (en) 2-aminoquinolines.
TH127978A (en) Eryl sulfonyl pyrazoline carboxamidine as 5-HT6 Antagonist.
TH101181A (en) Sulfonyl pyrazol and sulfonyl pyrazoline derivatives. Carboxamidine is 5-HT6 Antagonist.
WO2003014114A3 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TH101181B (en) Sulfonyl pyrazol and sulfonyl pyrazoline derivatives. Carboxamidine is 5-HT6 Antagonist.